US Tariffs Fatal for European Pharma
Trump's tariff policy is a considerable burden and a break with previous practice.
Pfizer
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
09.08.2024 • News
Pfizer Invests $100 Million to Upgrade Australian Site
Pfizer is investing nearly $100 million in a major upgrade to its manufacturing facility in Melbourne, Australia, that is intended to produce new antimicrobial treatments to address rising levels of antimicrobial resistance.
25.07.2024 • News
Pfizer Opens Expanded API Manufacturing Site in Singapore
Pfizer has commissioned its expanded, highly automated active pharmaceutical ingredient (API) manufacturing facility at the Tuas Biomedical Park in Singapore.
20.10.2023 • News
EU Commission Approves Pfizer’s Takeover of Seagen
The US pharmaceutical company Pfizer has been cleared to acquire Seagen, a biotech company focused on developing cancer treatments.
31.07.2023 • News
AstraZeneca Acquires Early-stage Gene Therapies from Pfizer
Alexion, AstraZeneca's rare disease division, has agreed to buy a portfolio of preclinical gene therapy programs and enabling technologies from competitor Pfizer for up to $1 billion, plus tiered royalties on sales.
25.07.2023 • News
Pfizer Warns of Drug Supply Disruption Following US-Tornado
Over 30 drugs, including painkiller fentanyl and anesthetic lidocaine, may see disruptions in supply after a tornado destroyed a warehouse at Pfizer's Rocky Mount facility in North Carolina, US, last week.
03.07.2023 • News
CSPC Pharmaceutical and Pfizer to Launch Local Brand of Paxlovid in China
Chinese drugmaker CSPC Pharmaceutical announced on Jun. 28, 2023, that it has signed a strategic partnership agreement with Pfizer to launch a local brand of the Covid-19 oral therapeutic treatment Paxlovid in China. The goal is to improve access to this treatment in China.
23.06.2023 • News
US Senators Seek Answers on Drug Shortages
In what is being billed as a bipartisan effort to address shortages along the US pharmaceutical supply chain, two senators — one Democrat, one Republican — have introduced legislation that calls for an investigation of the problems and development of a plan to reduce the country’s dependence on imported drugs.
20.06.2023 • News
FTC Intervention in Amgen-Horizon Deal Stuns Biopharma
The US Federal Trade Commission’s lawsuit to potentially block the $27.8 merger of Amgen and Horizon Therapeutics is creating heightened concern in the international biopharma sector.
13.06.2023 • News
Samsung Biologics and Pfizer in Biosimilars Pact
South Korean CDMO Samsung Biologics has entered into a long-term manufacturing partnership with major drugmaker Pfizer.
30.05.2023 • News
EU and Pfizer/BioNTech Amend Vaccine Pact
The European Commission and vaccine makers Pfizer and BioNTech have reached agreement on amending the bloc’s 2021 supply deal for the duo’s Comirnaty mRNA-based shot. The compromise that extends the last planned delivery date to 2026 follows months of discussion, with member states urging the Commission to renegotiate the controversial deal.
26.05.2023 • News
FDA Grants Full Approval to Pfizer’s Paxlovid
Pfizer's oral anti-viral Covid-19 treatment Paxlovid has won full approval from the US Food and Drug Administration (FDA) after Emergency Use Authorization was granted in late 2021.
Navigating Uncertainty in the Biopharma Market
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.
19.04.2023 • News
US Merck Snaps up Prometheus Biosciences for $10.8 Billion
Shares of Prometheus Biosciences soared on news that US drugs major Merck will acquire the company in an all-cash deal valued at roughly $200 per share, or $10.8 billion.
11.04.2023 • News
Court Threatens to Topple FDA’s Abortion Drug Approval
Conflicting decisions by federal courts in Texas and Washington on separate lawsuits involving mifepristone, one of the two drugs most widely used in medication-induced abortions, dominated US news over the Easter weekend. One of the rulings is thought likely to be challenged all the way to the Supreme Court.
05.04.2023 • News
Germany’s Merck Ends Bavencio Pact with Pfizer
Germany’s Merck will regain exclusive worldwide rights to develop, manufacture and commercialize the anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab) following the termination of its Alliance agreement with US drugs giant Pfizer, planned for the end of the second quarter.
21.03.2023 • News
Global Pharma Reduces Marketing Staff in India
As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their sales and marketing presence in India.
Centrally Controlled Logistics for Covid-19 Vaccines
Examples of national logistics solutions in the UK, the Netherlands and Belgium show how high availability and low costs can be brought down to a common denominator.
15.03.2023 • News
Pfizer Takes Seagen for $43 Billion
Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the Wall Street Journal reported that the two companies were in talks.
01.03.2023 • News
Pfizer in Talks to Take Cancer Biotech Seagen
Pfizer is in the early stage of talks to acquire Seagen (formerly Seattle Genetics), a US biotech focused on developing treatments for cancer, according to a report in the Wall Street Journal that cited people familiar with the matter. The purchase price could potentially be more than $30 billion.
17.02.2023 • News
Aristea Halts Clinical Trial, Dissolves Company
Safety findings in Phase 2 clinical trials have forced Aristea Therapeutics to stop developing its lead candidate RIST4721 for treating serious immune-mediated inflammatory diseases. As a consequence, Aristea’s management has decided to dissolve the company.
17.02.2023 • News
Pfizer CEO's Texts with EC Chief Trigger Lawsuit
Two years after European Commission president Ursula von der Leyen and Pfizer CEO Albert Bourla virtually wrapped up a major order for the Covid-19 vaccine Comirnaty that the US drugmaker markets with Germany’s BioNTech, the New York Times is suing the Commission in the European Court of Justice for its failure to make essential details of the negotiations public.
10.01.2023 • News
Viatris Forms Eye Care Unit from Acquisitions
Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on Jan. 3.
16.12.2022 • News
Chinese Distributor Inks Paxlovid Deal with Pfizer
As Covid cases continue to explode across the country, China Meheco Group Co, an internationally active manufacturer and distributor of pharmaceuticals chemicals and biologicals as well as Chinese traditional medical products, has struck a deal with Pfizer to distribute the US pharma giant’s oral antiviral Paxlovid in the People’s Republic.
15.12.2022 • News
Pfizer to Invest $750 million in Michigan
Pfizer is planning to invest $750 million in its Kalamazoo County, Michigan, production site – one of its biggest – to increase output of injectables and vaccines, including the investigational mRNA flu shot currently in Phase 3 clinical trials.
08.12.2022 • News
Pfizer Files Rebuttal of Moderna’s Patent Claim
Faced with a lawsuit from US rival Moderna, alleging that Pfizer and its German partner BioNTech infringed one of its patent for their top-selling Covid-19 vaccine Comirnaty, the New York US drugs giant said in a court filing that Comirnaty was based on independent research and wasn’t a Moderna copy.
06.12.2022 • News
Pfizer Doubles Dublin Biologicals Capacity
Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.
10.11.2022 • News
Pfizer/BioNTech Bivalent Covid Booster Wins Approvals
UK health regulator Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Pfizer/BioNTech bivalent Covid-19 vaccine for use as a booster in people 12 years and older.
28.10.2022 • News
Omicron-targeted Covid Boosters may not be Better
The newly launched bivalent mRNA-based Covid-19 booster shots from Moderna and Pfizer/BioNTech did not show a major improvement over the companies’ first-generation vaccines targeting the original strain, a small US study conducted by Columbia University and the University of Michigan has found. Detailed data have not yet been released.
20.10.2022 • News
EU Public Prosecutor Probes Vaccine Mega Order
The European Public Prosecutors Office (EPPO) has confirmed that it is looking into the EU Commission’s ordering of Covid-19 vaccines, with the probe thought to pertain in particular to order activity outside the usual purchasing channels.
04.10.2022 • News
Merck Grants Sinopharm Rights to Covid Pills
US drugs giant Merck & Co has granted Sinopharm exclusive import and distribution rights to its oral Covid treatment Lagevrio (molnupiravir) in China.
27.09.2022 • News
Unilever Chief to Quit sooner after failed GSK Bid
British-multinational consumer products giant Unilever has announced that its chief executive, Alan Jope, will retire at the end of 2023. The potentially earlier than planned departure announcement had been anticipated.
06.09.2022 • News
EMA’s CHMP Greenlights Omicron-1 Vaccines
The human medicines committee (CHMP) of EU drug regulator European Medicines Agency (EMA) has recommended approval of the updated Covid-19 vaccines of Pfizer-BioNTech and Moderna, combining protection against the original Omicron variant as well as the wild type that emerged in China in early 2020.
RightsDirect
AstraZeneca
CONTINUUS Pharmaceuticals, Inc.
Datamonitor Group
SchüllerConsulting
CHEManager International c/o Wiley-VCH GmbH
Thomson Reuters
Oracle Germany
Camelot Management Consultants AG
Mettler Toledo AutoChem Inc.
Sanofi S.A.
Arthur D. Little
Valneva SE
Bayer AG
Berlin Partner für Wirtschaft und Technologie GmbH
Movianto Deutschland GmbH
Scienceindustries - Wirtschaftsverband Chemie Pharma Life Sciences
Codexis
Lilly Deutschland GmbH
ISPE D/A/CH e.V.
Microinnova Engineering GmbH
Fitch Ratings
PureTech Systems
Metro Atlanta Chamber
Rentschler Biopharma SE
Merck & Co
GlobalData
PP Consulting
Iktos AI